David R. Gastfriend

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

David R. Gastfriend is a psychiatrist, internationally[1] recognized addiction treatment researcher,[2][3][4] the former Chief Executive Officer of the Treatment Research Institute (TRI),[5][6] and current Chief Medical Officer of DynamiCare Health.[7][8]

In April 2017, the Patient-Centered Outcomes Research Institute awarded a $13-million-dollar, 5-year grant to TRI to study addiction treatment with Gastfriend as principal investigator.[9][10][11][12] It will be the first large-scale trial to integrate the evidence-based practices in the Personalized Addiction Treatment to Health (PATH) model[10]—such as cognitive-behavioral relapse prevention, peer support, contingency management, and FDA-approved medications—and compare them with standard care practices typically offered to patients with opioid use disorders (OUD).[9][12] With 800 OUD patients, it will be one of the largest ever randomized controlled clinical trials of addiction treatment.[11][12]

Professional activities[edit]

A senior fellow of the American Society of Addiction Medicine (ASAM), Gastfriend led development of the ASAM criteria for placing patients in addiction treatment programs,[13] now standard in more than 30 US states.[1][14][15] These criteria became the basis of ASAM's assessment software "Continuum",[16] which will be deployed in the TRI study.[11]

Gastfriend was Vice President for Scientific Communications at the pharmaceutical company Alkermes[17] from 2004 to 2013. While there he co-authored a 2011 study[18] instrumental in getting FDA approval of injectable naltrexone (Vivitrol)[19] for the treatment of alcohol and opioid dependence.

In 2012 he received the John P. McGovern Award for "highly meritorious contributions to addiction and society in public policy, treatment, research or prevention" from the ASAM.[20] Gastfriend has worked as a consultant for the governments of Belgium, China, Iceland, Israel, Norway, Russia and the U.S.,[21][22] as well as the alcoholism and opioid-addition treatment company[23] BioCorRx.[24]

References[edit]

  1. ^ a b "Pennsylvania opts for a different tool to assess drug abuse | Reading Eagle - NEWS". Reading Eagle. Retrieved 2017-09-12.
  2. ^ Stateline, Pew's (2016-04-27). "This Opioid Treatment Model That Provides All Levels Of Care Is Spawning Imitators". Huffington Post. Retrieved 2017-09-12.
  3. ^ "Third of Philadelphians used prescription opioids in the last year, survey finds". Philly.com. Retrieved 2017-09-12.
  4. ^ Freyer, Felice (Dec 20, 2015). "Drug may give those leaving jail a better shot at recovery". The Boston Globe. Retrieved September 11, 2017.
  5. ^ "David R. Gastfriend M.D. : Executive Profile & Biography - Bloomberg". www.bloomberg.com. Retrieved 2017-09-11.
  6. ^ "Treatment Research Institute names new CEO". www.bizjournals.com. August 14, 2014. Retrieved 2017-09-11.
  7. ^ BioCorRx Inc. (September 12, 2017). "BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder". Nasdaq Marketwired. Retrieved September 12, 2017.
  8. ^ "BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017". UPTICK Newswire. 2017-08-15. Retrieved 2017-09-11.
  9. ^ a b "Treatment Research Institute Approved for $13 Million Research Funding Award by the U.S. Patient-Centered Outcomes Research Institute". PRWeb. Retrieved 2017-09-11.
  10. ^ a b "General health clinics, specialty care will go head-to-head in opioid treatment study | Addiction Professional Magazine". www.addictionpro.com. Retrieved 2017-09-11.
  11. ^ a b c "ASAM's Assessment Software CONTINUUM™ to be Used in Significant Clinical Trial". Continuum | ASAM Criteria Decision Engine. 2017-05-01. Retrieved 2017-09-12.
  12. ^ a b c "A Simple Large Trial of Patient-Centered Care for Opioid Use Disorders in Federally Qualified Healthcare Centers and Specialty Care Settings". www.pcori.org. Retrieved 2017-09-12.
  13. ^ "ASAM Patient Placement Criteria - Oversight and Revision" (PDF). May 2011. Retrieved September 11, 2017.
  14. ^ Kolsky, Gretchen D. (November 1, 2006). "Current State AOD Agency Practices Regarding the Use of Patient Placement Criteria (PPC) - An Update" (PDF). www.asam.org. The National Association of State Alcohol and Drug Abuse Directors.
  15. ^ Gamboa, Cesar (2017-04-03). "Pennsylvania to adopt ASAM guidelines for addiction treatment • Addiction Now | Substance Abuse, Drug Addiction and Recovery News Source". Addiction Now | Substance Abuse, Drug Addiction and Recovery News Source. Retrieved 2017-09-12.
  16. ^ "ASAM Criteria evolves into electronic tool | Behavioral Healthcare Magazine". www.behavioral.net. Retrieved 2017-09-12.
  17. ^ "The Last Shot — ProPublica". ProPublica. Alec MacGillis. 2017-06-27. Retrieved 2017-09-11.
  18. ^ Krupitsky, Evgeny; Nunes, Edward V.; Ling, Walter; Illeperuma, Ari; Gastfriend, David R.; Silverman, Bernard L. (April 28, 2011). "Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial" (PDF). The Lancet. 377: 1506–13. doi:10.1016/S0140. Retrieved June 11, 2017.
  19. ^ "A Shot in the Dark: Can Vivitrol Help Us Control Our Addictions?". 7 May 2013.
  20. ^ "ASAM Award Programs". www.asam.org. Retrieved 2017-09-11.
  21. ^ "Faculty". Addiction eXecutives Industry Summit. Retrieved 2017-09-12.
  22. ^ Center for Public Health Initiatives. "Evidence-based Public Health Week: From the Streets to the ER: The Opioid Analgesic Epidemic" (PDF). www.cphi.upenn.edu/. Retrieved September 12, 2017.
  23. ^ "Profile: BioCorRx Inc". Reuters. Retrieved 2017-09-11.
  24. ^ "Bloomberg: Company Overview of BioCorRx Inc". www.bloomberg.com. Retrieved 2017-09-11.

External links[edit]